Fluid biomarker and electrophysiological outcome measures for progressive MS trials
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fluid biomarker and electrophysiological outcome measures for progressive MS trials
Authors
Keywords
-
Journal
Multiple Sclerosis Journal
Volume 23, Issue 12, Pages 1600-1613
Publisher
SAGE Publications
Online
2017-10-18
DOI
10.1177/1352458517732844
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis
- (2017) I. Håkansson et al. EUROPEAN JOURNAL OF NEUROLOGY
- Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
- (2017) Diego Cadavid et al. LANCET NEUROLOGY
- A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS
- (2017) Martin Hardmeier et al. Multiple Sclerosis Journal
- Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report
- (2017) Vitalie Văcăraş et al. Neurologia i Neurochirurgia Polska
- Serum neurofilament is associated with progression of brain atrophy and disability in early MS
- (2017) Jens Kuhle et al. NEUROLOGY
- Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
- (2017) Niklas Mattsson et al. JAMA Neurology
- A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS
- (2017) Martin Hardmeier et al. Multiple Sclerosis Journal
- Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis
- (2016) Xavier Giffroy et al. BMC Neurology
- Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
- (2016) Jens Kuhle et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis
- (2016) J. Mellergård et al. EUROPEAN JOURNAL OF NEUROLOGY
- Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis
- (2016) Lenka Novakova et al. JOURNAL OF NEUROCHEMISTRY
- YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis
- (2016) Joachim Burman et al. JOURNAL OF NEUROIMMUNOLOGY
- Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis
- (2016) M.Alba Mañé-Martínez et al. JOURNAL OF NEUROIMMUNOLOGY
- Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum
- (2016) Carlo Wilke et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
- (2016) Lenka Novakova et al. Multiple Sclerosis Journal
- Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
- (2016) Jens Kuhle et al. Multiple Sclerosis Journal
- Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab
- (2016) Pierre de Flon et al. NEUROLOGY
- Neurofilament light chain level is a weak risk factor for the development of MS
- (2016) Georgina Arrambide et al. NEUROLOGY
- Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases
- (2016) Mehtap Bacioglu et al. NEURON
- Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
- (2016) Lenka Novakova et al. Multiple Sclerosis Journal
- Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
- (2016) Jens Kuhle et al. Multiple Sclerosis Journal
- Cognitive event-related potentials in multiple sclerosis: Correlation with MRI and neuropsychological findings
- (2016) Vasilios K. Kimiskidis et al. Multiple Sclerosis and Related Disorders
- Plasma neurofilament light chain predicts progression in progressive supranuclear palsy
- (2016) Julio C. Rojas et al. Annals of Clinical and Translational Neurology
- Neurofilament light chain: a biomarker for genetic frontotemporal dementia
- (2016) Lieke H. Meeter et al. Annals of Clinical and Translational Neurology
- Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
- (2016) Magnus Gisslén et al. EBioMedicine
- Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis
- (2015) Patrick Weydt et al. ANNALS OF NEUROLOGY
- Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes
- (2015) Ester Cantó et al. BRAIN
- Evoked potentials and disability in multiple sclerosis: A different perspective to a neglected method
- (2015) Nefati Kiylioglu et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Event related potential and response time give evidence for a physiological reserve in cognitive functioning in relapsing–remitting multiple sclerosis
- (2015) Mathias Sundgren et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
- (2015) M Alba Mañé Martínez et al. Multiple Sclerosis Journal
- Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis
- (2015) G Hinsinger et al. Multiple Sclerosis Journal
- Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
- (2015) C.-H. Lu et al. NEUROLOGY
- Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
- (2015) J. Kuhle et al. NEUROLOGY
- Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
- (2015) M Alba Mañé Martínez et al. Multiple Sclerosis Journal
- Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis
- (2015) G Hinsinger et al. Multiple Sclerosis Journal
- Multimodal neurophysiological evaluation of primary progressive multiple sclerosis – An increasingly valid biomarker, with limits
- (2015) L.J.W. Canham et al. Multiple Sclerosis and Related Disorders
- Assessing tissue damage in multiple sclerosis: a biomarker approach
- (2014) J. Burman et al. ACTA NEUROLOGICA SCANDINAVICA
- Reproducibility of multifocal visual evoked potential and traditional visual evoked potential in normal and multiple sclerosis eyes
- (2014) Divya Narayanan et al. DOCUMENTA OPHTHALMOLOGICA
- Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis
- (2014) L. M. Villar et al. EUROPEAN JOURNAL OF NEUROLOGY
- N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis
- (2014) Alessandro Trentini et al. JOURNAL OF NEUROLOGY
- Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients
- (2014) M. M. Gresle et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- No evidence for an association of osteopontin plasma levels with disease activity in multiple sclerosis
- (2014) Tessel F Runia et al. Multiple Sclerosis Journal
- Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis?
- (2014) Giovanni Di Maggio et al. Multiple Sclerosis Journal
- Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial
- (2014) J. Romme Christensen et al. NEUROLOGY
- Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis
- (2013) J. Kuhle et al. ACTA NEUROLOGICA SCANDINAVICA
- Central motor conduction time may predict response to fampridine in patients with multiple sclerosis
- (2013) D. Zeller et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis–osteopontin as a potential marker of clinical severity
- (2013) Levente Szalardy et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Body fluid biomarkers in multiple sclerosis
- (2013) Manuel Comabella et al. LANCET NEUROLOGY
- Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis
- (2013) Regina Schlaeger et al. Multiple Sclerosis Journal
- Evoked potentials are of little use in the diagnosis or monitoring of MS: No
- (2013) Oscar Fernández et al. Multiple Sclerosis Journal
- CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions
- (2013) Enrique Alvarez et al. Multiple Sclerosis Journal
- Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development
- (2013) Pia Kivisäkk et al. Multiple Sclerosis Journal
- Cortical plasticity predicts recovery from relapse in multiple sclerosis
- (2013) Francesco Mori et al. Multiple Sclerosis Journal
- Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
- (2013) Markus Axelsson et al. Multiple Sclerosis Journal
- A comparative study of CSF neurofilament light and heavy chain protein in MS
- (2013) Jens Kuhle et al. Multiple Sclerosis Journal
- Retest Reliability of Individual P3 Topography Assessed by High Density Electroencephalography
- (2013) Manuel Vázquez-Marrufo et al. PLoS One
- Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression
- (2013) Sharmilee Gnanapavan et al. PLoS One
- Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
- (2013) Johanna Gaiottino et al. PLoS One
- Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis
- (2013) Signe Modvig et al. PLoS One
- Serum GFAP levels in optic neuropathies
- (2012) Mithu Storoni et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study
- (2012) Peter Connick et al. LANCET NEUROLOGY
- CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis
- (2012) Jeppe Romme Christensen et al. Multiple Sclerosis Journal
- CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome
- (2012) M Khalil et al. Multiple Sclerosis Journal
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid
- (2011) Samia Ragheb et al. Multiple Sclerosis Journal
- Simvastatin improves final visual outcome in acute optic neuritis: a randomized study
- (2011) Anna Tsakiri et al. Multiple Sclerosis Journal
- The Use of Serum Glial Fibrillary Acidic Protein Measurements in the Diagnosis of Neuromyelitis Optica Spectrum Optic Neuritis
- (2011) Mithu Storoni et al. PLoS One
- Evidence for acute neurotoxicity after chemotherapy
- (2010) Axel Petzold et al. ANNALS OF NEUROLOGY
- Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
- (2010) Martin Gunnarsson et al. ANNALS OF NEUROLOGY
- Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
- (2010) Manuel Comabella et al. BRAIN
- Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis
- (2010) M. Axelsson et al. JOURNAL OF NEUROLOGY
- Neurofilament light as a prognostic marker in multiple sclerosis
- (2010) Jonatan Salzer et al. Multiple Sclerosis Journal
- Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis
- (2010) Lars Börnsen et al. Multiple Sclerosis Journal
- Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
- (2010) Mohsen Khademi et al. Multiple Sclerosis Journal
- Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations
- (2010) David M Rissin et al. NATURE BIOTECHNOLOGY
- Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study
- (2010) R. Takano et al. NEUROLOGY
- The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)
- (2010) Johannes Brettschneider et al. PLoS One
- The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers
- (2009) M. Khademi et al. EUROPEAN JOURNAL OF NEUROLOGY
- Serum levels of CXCL13 are elevated in active multiple sclerosis
- (2009) Eugene D Festa et al. Multiple Sclerosis Journal
- Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS
- (2009) F. Sellebjerg et al. NEUROLOGY
- Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis
- (2009) C. E. Teunissen et al. NEUROLOGY
- Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse
- (2009) Elizabeth Regina Comini Frota et al. NEUROSCIENCE LETTERS
- Multifocal VEP and OCT in optic neuritis: a topographical study of the structure–function relationship
- (2008) Alexander Klistorner et al. DOCUMENTA OPHTHALMOLOGICA
- A comparison of multifocal and conventional visual evoked potential techniques in patients with optic neuritis/multiple sclerosis
- (2008) Larissa K. Grover et al. DOCUMENTA OPHTHALMOLOGICA
- Phosphorylation and compactness of neurofilaments in multiple sclerosis: Indicators of axonal pathology
- (2008) Axel Petzold et al. EXPERIMENTAL NEUROLOGY
- The Phosphorylated Axonal Form of the Neurofilament Subunit NF-H (pNF-H) as a Blood Biomarker of Traumatic Brain Injury
- (2008) Kevin J. Anderson et al. JOURNAL OF NEUROTRAUMA
- Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event
- (2008) J.-C. Corvol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now